George Van Buren
- Oncology top 2%
- Molecular Biology top 10%
- Cancer Research top 5%
- Surgery top 10%
- Pulmonary and Respiratory Medicine top 10%
- Co-authors
- Fan FanLee M. EllisMichael J. GrayWilliam E. FisherNikolaos A. DallasLing XiaSomala MohammedSherry J. Lim
- Topics
- Pancreatic and Hepatic Oncology Research (29 papers)Pancreatitis Pathology and Treatment (14 papers)Renal cell carcinoma treatment (5 papers)
- Partner nations
- United StatesCanadaSouth Korea
In The Last Decade
George Van Buren
51 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 106
- Oncology 1.4k
- Molecular Biology 968
- Cancer Research 583
- Surgery 416
- Pulmonary and Respiratory Medicine 321
Countries citing papers authored by George Van Buren
This map shows the geographic impact of George Van Buren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Van Buren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Van Buren more than expected).
Fields of papers citing papers by George Van Buren
This network shows the impact of papers produced by George Van Buren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Van Buren. The network helps show where George Van Buren may publish in the future.
Co-authorship network of co-authors of George Van Buren
This figure shows the co-authorship network connecting the top 25 collaborators of George Van Buren. A scholar is included among the top collaborators of George Van Buren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Van Buren. George Van Buren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 3 | |
| 3 | 12 | |
| 4 | 50 | |
| 5 | 5 | |
| 6 | 8 | |
| 7 | 9 | |
| 8 | 22 | |
| 9 | 8 | |
| 10 | 1 | |
| 11 | 1 | |
| 12 | 26 | |
| 13 | 31 | |
| 14 | 32 | |
| 15 | 84 | |
| 16 | 36 | |
| 17 | 35 | |
| 18 | A monoclonal antibody targeting the human urokinase plasminogen activator receptor (uPAR) combined with bevacizumab inhibits the growth of colon cancer metastases in the liver: Differential effects mediated by tumor burden. | 2 |
| 19 | 51 | |
| 20 | 12 |
About George Van Buren
George Van Buren is a scholar working on Oncology, Cancer Research and Hepatology, having authored 52 papers that have together received 2.2k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (29 papers), Pancreatitis Pathology and Treatment (14 papers) and Renal cell carcinoma treatment (5 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (583 citations) and Molecular Biology (968 citations). George Van Buren has collaborated with scholars based in United States, Canada and South Korea. Frequent co-authors include Fan Fan, Lee M. Ellis, Michael J. Gray, William E. Fisher, Nikolaos A. Dallas, Ling Xia, Somala Mohammed, Sherry J. Lim, Ray Somcio and Puja Gaur. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.